John Landry

981 total citations
24 papers, 459 citations indexed

About

John Landry is a scholar working on Psychiatry and Mental health, Pharmacology and Molecular Biology. According to data from OpenAlex, John Landry has authored 24 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Psychiatry and Mental health, 6 papers in Pharmacology and 4 papers in Molecular Biology. Recurrent topics in John Landry's work include Schizophrenia research and treatment (9 papers), Bipolar Disorder and Treatment (6 papers) and Treatment of Major Depression (5 papers). John Landry is often cited by papers focused on Schizophrenia research and treatment (9 papers), Bipolar Disorder and Treatment (6 papers) and Treatment of Major Depression (5 papers). John Landry collaborates with scholars based in United States, Canada and United Kingdom. John Landry's co-authors include Holland C. Detke, Philippe Landreville, Lucie Baillargeon, Melissa P. DelBello, Shweta Urva, Tonya Quinlan, Jennifer A. Martin, David McDonnell, Corina Loghin and Victoria Reed and has published in prestigious journals such as PLoS ONE, Diabetes and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

John Landry

23 papers receiving 449 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Landry United States	12	176	107	100	94	76	24	459
Anita S. Kablinger United States	14	216 1.2×	63 0.6×	84 0.8×	78 0.8×	133 1.8×	50	641
Madhubhashinee Dayabandara Sri Lanka	7	249 1.4×	57 0.5×	119 1.2×	80 0.9×	72 0.9×	17	465
Chathurie Suraweera Sri Lanka	9	308 1.8×	82 0.8×	116 1.2×	83 0.9×	76 1.0×	26	581
Maria Teresa Cruz Lourenço Canada	12	177 1.0×	99 0.9×	86 0.9×	59 0.6×	57 0.8×	19	552
Carla Conroy United States	14	404 2.3×	46 0.4×	62 0.6×	111 1.2×	115 1.5×	30	624
S. S. Ratnatunga Sri Lanka	4	230 1.3×	56 0.5×	105 1.1×	72 0.8×	47 0.6×	7	402
J. Caudle United States	13	234 1.3×	72 0.7×	202 2.0×	37 0.4×	91 1.2×	28	698
Petros Petrikis Greece	15	187 1.1×	61 0.6×	51 0.5×	31 0.3×	105 1.4×	41	553
Robyn McAskill United Kingdom	4	244 1.4×	59 0.6×	72 0.7×	82 0.9×	34 0.4×	6	396
J.M. Hernández Sánchez Spain	3	424 2.4×	37 0.3×	217 2.2×	118 1.3×	91 1.2×	9	563

Countries citing papers authored by John Landry

Since Specialization

Citations

This map shows the geographic impact of John Landry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Landry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Landry more than expected).

Fields of papers citing papers by John Landry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Landry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Landry. The network helps show where John Landry may publish in the future.

Co-authorship network of co-authors of John Landry

This figure shows the co-authorship network connecting the top 25 collaborators of John Landry. A scholar is included among the top collaborators of John Landry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Landry. John Landry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luffer‐Atlas, Debra, Darren Wilbraham, Maria M. Posada, et al.. (2023). Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P‐Glycoprotein and Breast Cancer Resistance Protein Substrates. The Journal of Clinical Pharmacology. 64(1). 94–102.

Urva, Shweta, Tonya Quinlan, John Landry, et al.. (2022). Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clinical Pharmacokinetics. 61(7). 1057–1067. 21 indexed citations

Urva, Shweta, Tonya Quinlan, John Landry, Jennifer A. Martin, & Corina Loghin. (2021). Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clinical Pharmacokinetics. 60(8). 1049–1059. 41 indexed citations

Urva, Shweta, et al.. (2021). Renal Impairment Has No Impact on the Clinical Pharmacokinetics of Tirzepatide. Diabetologie und Stoffwechsel. 1 indexed citations

Goemans, Nathalie, Brenda Wong, M. van den Hauwe, et al.. (2020). Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration. PLoS ONE. 15(6). e0232870–e0232870. 23 indexed citations

Urva, Shweta, Tonya Quinlan, John Landry, Jennifer C. Martin, & Corina Loghin. (2020). 971-P: Renal Impairment Has No Impact on the Clinical Pharmacokinetics of Tirzepatide. Diabetes. 69(Supplement_1). 1 indexed citations

Small, David S., et al.. (2019). Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending‐dose study. British Journal of Clinical Pharmacology. 85(10). 2302–2309. 7 indexed citations

Meyers, Kristin J., et al.. (2017). Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: Results from a large observational study. BJPsych Open. 3(4). 186–192. 14 indexed citations

Walker, Daniel, Melissa P. DelBello, John Landry, Deborah N. D’Souza, & Holland C. Detke. (2017). Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination. Child and Adolescent Psychiatry and Mental Health. 11(1). 34–34. 9 indexed citations

10.

Detke, Holland C., Melissa P. DelBello, John Landry, et al.. (2016). A 52-Week Study of Olanzapine with a Randomized Behavioral Weight Counseling Intervention in Adolescents with Schizophrenia or Bipolar I Disorder. Journal of Child and Adolescent Psychopharmacology. 26(10). 922–934. 11 indexed citations

11.

Anand, Ernie, et al.. (2016). Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being. Neuropsychiatric Disease and Treatment. Volume 12. 2737–2743. 3 indexed citations

12.

Jones, Meghan, J. Scott Andrews, Douglas E. Faries, et al.. (2015). Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study. BMC Psychiatry. 15(1). 278–278. 5 indexed citations

13.

McDonnell, David, John Landry, & Holland C. Detke. (2014). Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology. 29(6). 322–331. 22 indexed citations

14.

Brunner, Eric J., Mauricio Tohen, Olawale Osuntokun, John Landry, & Michael E. Thase. (2014). Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology. 39(11). 2549–2559. 36 indexed citations

15.

Detke, Holland C., et al.. (2014). Olanzapine/Fluoxetine Combination in Children and Adolescents With Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the American Academy of Child & Adolescent Psychiatry. 54(3). 217–224. 48 indexed citations

16.

Detke, Holland C., John Lauriello, John Landry, & David McDonnell. (2014). Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment. International Journal of Methods in Psychiatric Research. 23(4). 439–450. 3 indexed citations

17.

Bowering, Keith, et al.. (2012). A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti‐hyperglycaemic medication: results of the PARADIGM study. Diabetic Medicine. 29(9). e263–72. 32 indexed citations

18.

Karagianis, J., John Landry, Vicki Poole Hoffmann, et al.. (2010). An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study. International Journal of Clinical Practice. 64(11). 1520–1529. 2 indexed citations

19.

Karagianis, J., Loren D. Grossman, John Landry, et al.. (2009). A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS Study. Schizophrenia Research. 113(1). 41–48. 26 indexed citations

20.

Landreville, Philippe, et al.. (2001). Older Adults' Acceptance of Psychological and Pharmacological Treatments for Depression. The Journals of Gerontology Series B. 56(5). P285–P291. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact